Aratana Therapeutics

Aratana Therapeutics, Inc. is a fast-growing pet therapeutics company headquartered in Kansas City with offices in Boston, Massachusetts, San Diego, California and Leuven, Belgium. We are focused on licensing, developing and commercializing innovative biopharmaceutical products for cats and dogs. Our company means "new beginning" and it defines our mission to develop safe and effective therapeutics for serious unmet and underserved medical needs in pets, and to deliver these cutting-edge options to veterinarians. We are uniquely positioned because we're operating at the intersection of human and animal science - taking advances in human medicine and applying to the unmet and underserved needs of pets.
Aratana means “new beginning” and it defines our mission of developing safe and effective therapeutics for unmet or underserved medical conditions in pets. Our goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. We believe pets are family and they deserve the best quality care.
Aratana Therapeutics was founded in 2010, in the heart of the Kansas City Animal Health Corridor, with the vision of finding the best human drug development opportunities and applying them to veterinary medicine. Our team of experts, who have decades of experience in human health, animal health, biotechnology and other functional areas, paired with a lifelong love for pets, are committed to helping raise the standard of care for pets in order to help extend and improve the lives of cats and dogs. We have the pleasure of coming to work every day and putting our passion into making a difference for pets.
Our dedication has led us to develop a pipeline of novel therapeutics focused in area of osteoarthritis, post-operative pain management, inappetence, allergy, lymphoma and osteosarcoma, viral diseases and other unmet pet health needs.

Company Growth (employees)
Type
Public
HQ
Leawood, US
Founded
2010
Size (employees)
56 (est)
Aratana Therapeutics was founded in 2010 and is headquartered in Leawood, US

Key People at Aratana Therapeutics

Louise MawHinney

Louise MawHinney

CFO
Ernst Heinen

Ernst Heinen

Head of Drug Evaluation and Development
John Ayers

John Ayers

General Counsel & Secretary
James Miller

James Miller

Controller
Marie-Paul Lachaud

Marie-Paul Lachaud

Head of Business & Product Development Europe

Aratana Therapeutics Office Locations

Aratana Therapeutics has offices in Leawood, Boston, San Diego, Leuven
Leawood, US (HQ)
340 11400 Tomahawk Creek Pkwy
Leuven, BE
1 Ambachtenlaan
San Diego, US
200a 10451 Roselle St
Boston, US
545 Boylston St

Aratana Therapeutics Metrics

Aratana Therapeutics Financial Metrics

Revenue (2016)

$38.6 m

Revenue growth (2015-16), %

5586%

Gross profit

$35.4 m

Gross profit margin (2016), %

92%

Net income (2016)

($33.6 m)

Market capitalization (21-Mar-2017)

$195.4 m

Closing share price (21-Mar-2017)

$5.3

Cash (31-Dec-2016)

$87.3 m
Aratana Therapeutics's current market capitalization is $195.4 m.
Aratana Therapeutics's revenue was reported to be $38.6 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$123 k$767 k$678 k$38.6 m

Revenue growth, %

524%(12%)5586%

Cost of goods sold

$108 k$365 k$3.1 m

Gross profit

$15 k$434 k$313 k$35.4 m

Gross profit Margin, %

12%57%46%92%

Operating expense total

$42 m$42 m$89.8 m$69.4 m

EBIT

($41.9 m)($41.6 m)($89.5 m)($30.8 m)

EBIT margin, %

(34102%)(5425%)(13200%)(80%)

Interest expense

$432 k$1.6 m$3.4 m

Interest income

$75 k$189 k$385 k

Pre tax profit

($19.7 m)($85.8 m)($33.6 m)

Income tax expense

$15.5 m$1.7 m$1.7 m

Net Income

($26.2 m)($38.8 m)($84.1 m)($33.6 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$41.1 m$9.8 m$26.8 m$87.3 m

Accounts Receivable

$352 k$60 k$87 k

Inventories

$274 k$427 k$1.3 m$11.1 m

Current Assets

$48.5 m$99.9 m$89 m$101.5 m

PP&E

$98 k$620 k$2.6 m$1.9 m

Goodwill

$20.8 m$41.4 m$39.8 m$39.4 m

Total Assets

$115.5 m$207.9 m$147.1 m$151.4 m

Accounts Payable

$2.3 m$1.5 m$1.4 m$7.4 m

Current Liabilities

$16.9 m$9.5 m$5.7 m$34.7 m

Additional Paid-in Capital

$112.5 m$255 m$263.9 m$286.9 m

Retained Earnings

($68 m)($152 m)($185.6 m)

Total Equity

$86 m$181.8 m$101.6 m$90.4 m

Financial Leverage

1.3 x1.1 x1.4 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($4.3 m)($38.8 m)($84.1 m)($33.6 m)

Depreciation and Amortization

$395 k$2 m$1.8 m$379 k

Accounts Receivable

($102 k)$281 k($27 k)

Inventories

($372 k)($879 k)($15 m)

Accounts Payable

$1.5 m($1.1 m)($117 k)$6.2 m

Cash From Operating Activities

($16.2 m)($32.2 m)($38.5 m)($11.3 m)

Cash From Investing Activities

($29.2 m)($100.1 m)$33.7 m$57.3 m

Cash From Financing Activities

$72.5 m$101 m$21.9 m$14.6 m

Interest Paid

$357 k$942 k

Aratana Therapeutics Market Value History

Aratana Therapeutics Online Presence

Aratana Therapeutics Company Life

You may also be interested in